Facing a new increase in worldwide Malaria cases since 2015, a global technical strategy (GTS) has been implemented by the World Health Organization (WHO) aiming a decrease of 90% of Malaria impact by 2030.This requires the development of detection devices, very easy to use, collecting data and resistant to tropical conditions devoted to:• detect persistent undetectable parasitaemia in people without symptoms or recent history of malaria• detect the main causes of fever, whereof malaria• be a simplified control reference for other diagnostics
Facing a new increase in worldwide Malaria cases since 2015, a global strategy has been developed aiming a 90% decrease in Malaria exposure by 2030. This aim requires the development of a test devoted to detect persistant undetectable parasitaemia in people without symptoms or recent history of malaria.
Malaria pre-elimination and elimination
According to WHO: Malaria elimination is the interruption of local transmission (reduction to zero incidence of indigenous cases) of a specified malaria parasite species in a defined geographic area; continued measures are required to prevent re-establishment of transmission. WHO grants this certification when a country has proven, beyond reasonable doubt, that the chain of local transmission of all human malaria parasites has been interrupted nationwide for at least the past 3 consecutive years; and that a fully functional surveillance and response system that can prevent re-establishment of indigenous transmission is in place. Based on those requirements, the detection of circulating parasites in the whole population of an endemic country will be a cornerstone of the malaria elimination certification. There is no doubt that beyond the public health interest of such a certification, the economic and political impacts of becoming a malaria free country are huge.
Our products
Magnetrap develops Malaria detection tools for symptomatic and asymptomatic carriers considering as the heart of its activities the end users at the point-of-care.
Our solutions are based on several fields experience and a true knowledge of the needs for deseases detection. We ensure the long-term economical viability of the product and the whole value chain.
The Advisory board
Pr. Robert Sauerwein
Scientific advisor - Chair of Medical Parasitology Radbout University (NL)
Jacques-François Martin
Business advisor Founder of GAVI (Global Alliance for Vaccines and Immunization)
Dr. Joris Vandeputte
Founder President of the International Alliance for Biological Standardization
Management Team
Peter Vandeputte
CEO & Company founder Experienced executive in international groups especially in Africa
ir. Alain Martin
COO
30+ years exp. in Executive & Project Mgt within Siemens group
Pr. Bertrand Blankert
CSO Head of the Dpt. of Pharma. Analysis UMons
